Respiratory viral infections occur more frequently during the winter months1 and are a risk factor for respiratory exacerbations:2,3
There are several factors to consider when choosing an aerosol drug delivery device:
Aerogen: supporting you through winter
In a study of patients in an emergency department requiring treatment with an aerosolised bronchodilator:
0
of patients achieved symptom control with one 2.5 mg salbutamol dose 7
0
median reduction in ED length of stay per patient with Aerogen Ultra versus jet nebuliser 7
0
reduction in admission rates with Aerogen Ultra versus jet nebuliser 7
0
higher discharge rate with Aerogen Ultra versus jet nebuliser 7
Aerogen helps mitigate fugitive emissions8,9
Significantly lower fugitive aerosol concentrations were reported with Aerogen and mask or mouthpiece versus jet nebuliser during self-ventilation (P<0.05)†8
Aerogen can be used throughout the hospital10
If escalation of care is required, the Aerogen Solo system can facilitate aerosol drug delivery at every stage of a patient's respiratory journey (SV, HF, NIV, IMV),10 supporting continuity of care.
Aerogen supports a calm environment
Quick and easy to set up10
Virtually silent during drug delivery10,11
Compatible with all standard aerosol/valved face masks, to meet varied patient needs10
Aerogen Solo
Aerogen Solo can support aerosol drug delivery at every stage of a patient’s respiratory journey: during IMV, NIV, HF and SV.1
- Quick and easy to set up10
- Virtually silent10,11
- Single patient use10
- 28 days intermittent or 7 days continuous use10
- No added flow10
- Refill medication cup without opening the circuit10
- 6 mL cup10
- Can be placed at the wye or at the humidifier10
†Defined as fugitive aerosol concentrations with jet nebuliser vs Aerogen with a mask at particle sizes of 1.0–5 μm and with a mouthpiece at particle sizes of 0.5–3 μm (all P<0.05) when self-ventilating. Study performed in healthy subjects.
- Moriyama M, Hugentobler WJ, Iwasaki A. Annu Rev Virol. 2020;7(1):83-101.
- 2022 GINA Report, Global Strategy for Asthma Management and Prevention. Available at: www.ginasthma.org/gina-reports/ Accessed: September 2023.
- Global Initiative for Chronic Obstructive Lung Disease: Global strategy for prevention, diagnosis and management of COPD, 2023. Available at: www.goldcopd.org/2023-gold-report-2/. Accessed: September 2023.
- Jin X, Ren J, Li R, et al. EClinicalMedicine. 2021;37:100986.
- Ari A. Ann Transl Med. 2021;9(7):593.
- Corcoran TE. Ann Transl Med. 2021;9(7):595.
- Dunne RB, Shortt S. Am J Emerg Med. 2018;36(4):641-646.
- Harnois LJ, Alolaiwat AA, Jing G, Fink JB, Dhand R, Li J. Respir Care. 2022;67(4):394-403.
- McGrath JA, O’Sullivan A, Bennett G, et al. Pharmaceutics. 2019;11(2):75.
- 30-354 Rev U Aerogen Solo System Instruction Manual.
- Royal National Institute for Deaf People (RNID). How loud is too loud? Available at: https://rnid.org.uk/information-and-support/ear-health/protect-your-hearing/how-loud-is-too-loud/ Accessed: November 2023
GL-2220-1-EN